PUNE, India, June 2, 2016 /PRNewswire-iReach/ -- Despite Major Patent Expiries, Hematological Cancers Market will exceed $70 billion by 2021
Photo - http://photos.prnewswire.com/prnh/20160602/374756
The market size for hematological cancers, which covers leukemia, lymphoma and myeloma, is expected to more than double over the forecast period, from $30.7
Latest report, Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market provides analysis of the hematological cancers market space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2015 and forecast to 2022.
Global Non-Hematological Cancers Market will almost double to $141 billion by 2021
The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%. This robust growth will occur in spite of the patent expiries of a number of very commercially successful products, including Avastin, Erbitux and Herceptin. Market drivers will include the increasing prevalence of cancer globally, and the introduction of more targeted treatments.
Latest report Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics provides analysis of the global non-hematological cancers treatment space, specifically breast, colorectal, lung and prostate cancer. It features annualized market data from 2014 and forecast to 2021, as well as details on the current clinical and commercial landscape.
Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WiseGuy Reports
Subscribe to our Free Newsletters!